Company news

Oruka Therapeutics, Inc. news in 2024

Oruka Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

December 18, 2024

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

December 17, 2024

Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference

November 18, 2024

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 12, 2024

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

September 24, 2024

Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19

September 11, 2024

Oruka Therapeutics Announces $200 Million Private Placement

September 11, 2024

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

August 22, 2024

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

July 31, 2024

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

April 24, 2024

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

April 2, 2024

ARCA biopharma Announces 2023 Financial Results

January 31, 2024

Decks in 2024